Pulmonx Reaffirms 2026 Revenue Guidance Following Q3 Growth
Pulmonx (LUNG) reported third-quarter 2026 total worldwide revenue of $22.8 million, signaling a return to year-over-year growth for the company. Management expressed confidence in their trajectory by reiterating full-year revenue guidance in the range of $90 million to $92 million. In addition to revenue projections, the company provided guidance for operating expenses, estimating them to be between $108 million and $109 million for the year. CEO Glendon French highlighted the quarter's performance as a significant milestone in the organization's growth cycle.
Tickers: $LUNG